Thromboembolism remains an extremely rare side effect of COVID-19 vaccination, and the benefits of vaccination against COVID-19 continue to outweigh the risks of side effects. The scientific community should have confidence in the safety of the SARS-CoV-2 vaccines when considering solutions to unwanted side effects. This study explores the intricate immunological pathways associated with vaccine-induced immune thrombotic thrombocytopenia (VITT), focusing on the COVID-19 vaccine. The development of VITT is linked to thrombosis, where viral proteins and free DNA in the vaccine bind to platelet factor 4, generating a neo-antigen that induces the production of antibodies promoting platelet activation and clotting. The study sheds light on the complex immunological responses contributing to VITT and its distinction from related syndromes.
Ah Young Kim, Wongi Woo, Dong Keon Yon, Seung Won Lee, Jae Won Yang, Ji Hong Kim, Seoyeon Park, Ai Koyanagi, Min Seo Kim, Sungsoo Lee, Jae Il Shin, Lee Smith
Discussion(0)
No comments yet. Be the first to comment.